These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33044997)

  • 1. Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy with good baseline visual acuity.
    Hayashida M; Miki A; Nakai S; Matsumiya W; Imai H; Kusuhara S; Nakamura M
    PLoS One; 2020; 15(10):e0240557. PubMed ID: 33044997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.
    Ohkuma Y; Hayashi T; Sakai T; Watanabe A; Tsuneoka H
    Graefes Arch Clin Exp Ophthalmol; 2013 Aug; 251(8):1909-17. PubMed ID: 23456099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aniseikonia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy.
    Chubachi-Kamimura A; Miki A; Hayashida-Hirano M; Kishimoto-Kishi M; Okuda M; Matsumiya W; Imai H; Kusuhara S; Nakamura M
    Sci Rep; 2023 Oct; 13(1):17133. PubMed ID: 37816824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy.
    Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
    Retina; 2014 May; 34(5):964-70. PubMed ID: 24406387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
    Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M
    Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic changes and visual outcomes in resolved central serous chorioretinopathy treated with ranibizumab.
    Ozdemir O; Erol MK
    Cutan Ocul Toxicol; 2014 Jun; 33(2):122-6. PubMed ID: 23848591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Factors Associated with Low-Contrast Visual Acuity after Reduced-Fluence Photodynamic Therapy in Patients with Resolved Central Serous Chorioretinopathy and Good Baseline Visual Acuity.
    Chubachi A; Miki A; Hayashida M; Sakamoto M; Imai H; Kusuhara S; Nakamura M
    Pharmaceuticals (Basel); 2021 Mar; 14(4):. PubMed ID: 33800693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy.
    Yu J; Lei Y; Chang Q; Xu G; Ye X; Li L; Jiang C
    BMC Ophthalmol; 2019 Mar; 19(1):84. PubMed ID: 30922273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic factors associated with treatment response to reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Hayashida M; Miki A; Nakai S; Matsumiya W; Imai H; Kusuhara S; Honda S; Nakamura M
    Mol Vis; 2020; 26():505-509. PubMed ID: 32774081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-Term Retinal Sensitivity and Metamorphopsia Changes following Half-Fluence Photodynamic Therapy in Central Serous Chorioretinopathy.
    Casalino G; Del Turco C; Corvi F; Rafaeli O; Bandello F; Querques G
    Ophthalmic Res; 2016; 56(1):23-9. PubMed ID: 27003789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy.
    Matsumoto H; Sato T; Kishi S
    Am J Ophthalmol; 2009 Jul; 148(1):105-10.e1. PubMed ID: 19327740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELONGATED PHOTORECEPTOR OUTER SEGMENT LENGTH AND PROGNOSIS OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Asano KS; Asaoka R; Asano S; Azuma K; Inoue T; Obata R
    Retina; 2020 Apr; 40(4):750-757. PubMed ID: 30640283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Shinoda K; Imamura Y; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
    Am J Ophthalmol; 2012 Sep; 154(3):579-85. PubMed ID: 22818904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical parameters related to metamorphopsia outcome in patients with resolved central serous chorioretinopathy using M-CHARTS: retrospective cohort study.
    Bae S; Jin K; Kim H; Bae SH
    BMC Ophthalmol; 2015 Dec; 15():180. PubMed ID: 26677843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of metamorphopsia in patients with central serous chorioretinopathy.
    Bae SW; Chae JB
    Indian J Ophthalmol; 2013 Apr; 61(4):172-5. PubMed ID: 23685489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
    Liu Y; Li L; Xu G; Wang W
    Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Photodynamic therapy for treatment of chronic or recurrent central serous chorioretinopathy].
    Li L; Yuan F; Xu GZ; Wang WJ
    Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):106-13. PubMed ID: 22490944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy for chronic central serous chorioretinopathy.
    Ruiz-Moreno JM; Lugo FL; Armadá F; Silva R; Montero JA; Arevalo JF; Arias L; Gómez-Ulla F
    Acta Ophthalmol; 2010 May; 88(3):371-6. PubMed ID: 19958296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy.
    van Rijssen TJ; Mohabati D; Dijkman G; Theelen T; de Jong EK; van Dijk EHC; Boon CJF
    PLoS One; 2018; 13(8):e0202549. PubMed ID: 30142176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.